We conducted secondary desk research into travel behaviour and travel volumes to relevant regions, as well as identifying private vaccination providers in each country. We then initiated a first round of exploratory pilot interviews with a small number of participants in both North America and Europe and Sub Saharan African countries. This allowed us to understand the opportunity both in markets expected to have high volumes of travel to regions affected by the vaccine-preventable disease, and markets in close proximity to those regions.
From this, we determined who the key players in vaccine decisions were, and which markets to best target for the full research sample. Once the full sample was agreed with our client, we proceeded to conduct interviews exploring the potential opportunity for the vaccine, in terms of who would be purchasing it. We also tested stakeholders’ reactions to a product profile of the vaccine in order to identify potential drivers and barriers to uptake.
Through our multiwave approach we were able to present our client with a clear account of the anticipated usage, impact on current practice and general expectations of product x. Our findings enabled us to share with our client a complete account of the barriers to uptake for their product, whilst sharing insightful ways to overcome the obstacles of the AKI market.